Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry

Secukinumab is a fully human IgG1 antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin-17A. Secukinumab is an effective and well-tolerated treatment for plaque psoriasis. There is a limited real-word evidence for dose optimisation of secukinumab based on clinic...

Full description

Saved in:
Bibliographic Details
Published in:Archives of Dermatological Research 2024-06, Vol.316 (7), p.362, Article 362
Main Authors: Papp, Kim A., Gooderham, Melinda, Lynde, Charles, Brassard, Danielle, Al-Mohammedi, Faisal, Prajapati, Vimal H., Delorme, Isabelle, Albrecht, Lorne, Haydey, Richard, Alam, Maryam Shayesteh, Beecker, Jennifer, Siddha, Sanjay, Maguin, Marie, Farag, Mahmoud S., Vieira, Antonio, Rihakova, Lenka, Langley, Richard G.
Format: Article
Language:English
Subjects:
Body weight
Dermatology
Drug dosages
Immunoglobulin A
Immunoglobulin G
Medicine
Medicine & Public Health
Monoclonal antibodies
Original Paper
Patients
Psoriasis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Secukinumab is a fully human IgG1 antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin-17A. Secukinumab is an effective and well-tolerated treatment for plaque psoriasis. There is a limited real-word evidence for dose optimisation of secukinumab based on clinical response. PURE is a multi-national, prospective, observational study in patients with moderate to severe chronic plaque psoriasis in Canada and Latin America, assessing the real-world safety and effectiveness of secukinumab and other indicated therapies. The aim of the current snapshot analysis was to evaluate the effectiveness and safety of on-label dose and updosed secukinumab in patients with plaque psoriasis enrolled in the PURE study. At the time of analysis, 676 patients received secukinumab, of which 84.6% ( n  = 572) remained on the on-label dose, while 15.4% ( n  = 104) were updosed. With on-label secukinumab, the absolute Psoriasis Area and Severity Index (PASI) score was reduced from 13.6 at baseline to 1.2 over 36 months, with treatment persistence of 73% at 40 months. At Month 36, 73.2% of the patients receiving on-label secukinumab achieved Investigator’s Global Assessment (IGA) 0/1. With updosed secukinumab (300 mg every 2 weeks, 300 mg every 3 weeks, 450 mg every 4 weeks, or 450 mg every 3 weeks), 57.9% of the patients showed improvement in the absolute PASI score at the first visit after updosing, with treatment persistence of 50% at 12 months after updosing. At Month 15, 40% of patients receiving updosed secukinumab achieved IGA 0/1. Patients with previous biologic exposure (odds ratio [OR]: 3.25; 95% confidence interval [CI]: 2.03, 5.18, p  
ISSN:1432-069X
0340-3696
1432-069X
DOI:10.1007/s00403-024-03122-w